The NHE3 sodium transport inhibitor was approved for use after results from 2 clinical trials showed increased bowel movements and decreased abdominal pain among individuals with IBS-C.
The FDA have identified several ingredients that may be connected to the recent reports of individuals with severe respiratory illness in connection with use of electronic smoking products.
The FDA have identified several ingredients that may be connected to the recent reports of individuals with severe respiratory illness in connection with use of electronic smoking products.
The FDA have identified several ingredients that may be connected to the recent reports of individuals with severe respiratory illness in connection with use of electronic smoking products.
Previously to this drug’s approval, there were no treatment options for adults with interstitial lung disease associated with systemic sclerosis or scleroderma.
Previously to this drug’s approval, there were no treatment options for adults with interstitial lung disease associated with systemic sclerosis or scleroderma.
The FDA issued a drug safety warning after more than 60 individuals experienced liver injury after they received treatment with 1 of 3 medications for hepatitis C virus.
The FDA issued a drug safety warning after more than 60 individuals experienced liver injury after they received treatment with 1 of 3 medications for hepatitis C virus.
The FDA issued a drug safety warning after more than 60 individuals experienced liver injury after they received treatment with 1 of 3 medications for hepatitis C virus.
